Guidelines for management of hypertension: Report of the third working party of the British Hypertension Society

Journal of Human Hypertension

Volumn 13, Issue 9, 1999, Pages 569-592

  Ramsay, L E ^b   Williams, Bryan ^a   Johnston, G D ^b   MacGregor, G A ^b   Poston, L ^b   Potter, J F ^b   Poulter, N R ^b   Russell, G ^b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b NONE

Author keywords

BHS; Management of hypertension

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHOLESTEROL; GLUCOSE; ORAL CONTRACEPTIVE AGENT; STATIN; THIAZIDE DIURETIC AGENT;

AGE; ARTICLE; BORDERLINE HYPERTENSION; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CORONARY RISK; DIABETES CONTROL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; GLUCOSE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; MEDICAL AUDIT; PRACTICE GUIDELINE; PREGNANCY; RACE DIFFERENCE; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; TARGET ORGAN;

EID: 0032874699     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000917     Document Type: Article

References (170)

1. Swales JD et al. Treating mild hypertension. BMJ 1989; 298: 694-698.
2. Sever P et al. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ 1993; 306: 983-987.
3. Hansson L et al, for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
4. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462.
5. Curb JD, Pressel SL, Cutler JA et al, for the Systolic Hypertension in the Elderly Program Co-operative Research Group. Advantage of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996; 276: 1886-1892.
6. United Kingdom prospective diabetes study group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. BMJ 1998; 317: 703-713.
7. Tuomilehto J et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Syst Eur Investigators. N Engl J Med 1999; 340: 677-684.
8. Staessen JA, Fagard R, Thijs L et al, for the Systolic Hypertension-Europe (Syst-Eur) Trial Investigators. Morbidity and mortality in the placebo-controlled European Trial on Isolated Systolic Hypertension in the Elderly. Lancet 1997; 360: 757-764.
9. Neaton JD et al, for the Treatment of Mild Hypertension Study Research Group. Treatment of Mild Hypertension Study. Final results. JAMA 1993; 270: 713-724.
10. Materson BJ et al, for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328: 914-921.
11. Philipp T et al, on behalf of the HANE Trial Research Group. Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. BMJ 1997; 315: 154-159.
12. Appel LJ et al, for the DASH Collaborative Research Group. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 1997; 336: 1117-1124.
13. Applegate WB et al. Nonpharmacologic intervention to reduce blood pressure in older patients with mild hypertension. Arch Intern Med 1992; 152: 1162-1166.
14. Cushman WC et al, for the PATHS Group. Prevention and Treatment of Hypertension Study (PATHS): Effects of an alcohol treatment program on blood pressure. Arch Intern Med 1998; 158: 1197-1207.
15. The Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure: the Trials of Hypertension Prevention, Phase II. Arch Intern Med 1997; 157: 657-667.
16. Whelton PK et al, for the TONE Collaborative Research Group. Sodium reduction and weight loss in the treatment of hypertension in older persons. A randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). JAMA 1998; 279: 839-846.
17. Stanton AV. Calcium channel blockers. BMJ 1998; 316: 1471-1472.
18. Cutler JA. Calcium-channel blockers for hypertension - uncertainty continues. N Engl J Med 1998; 338: 679-681.
19. Dickerson JEC, Garratt CJ, Brown MJ. Management of hypertension in general practice: agreements with and variations from the British Hypertension Society guidelines. J Hum Hypertens 1995; 9: 835-839.
20. Dickerson JEC, Brown MJ. Influence of age on general practitioners' definition and treatment of hypertension. BMJ 1995; 310: 574.
21. Smith WCS, Lee AJ, Crombie IK, Tunstall-Pedoe H. Control of blood pressure in Scotland: the rule of halves. BMJ 1990; 300: 981-983.
22. Mashru M, Lant A. Interpractice audit of diagnosis and management of hypertension in primary care: educational intervention and review of medical records. BMJ 1997; 314: 942-946.
23. Colhoun HM, Dong W, Poulter NR. Blood pressure screening, management and control in England, results from the health survey for England 1994. J Hypertens 1998; 16: 747-753.
24. Collins R et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
25. Isles CG et al. Mortality in patients of the Glasgow blood pressure clinic. J Hypertens 1986; 4: 141-156.
26. Clausen J, Jenson G. Blood pressure and mortality: an epidemiological survey with 10 years follow-up. J Hum Hypertens 1992; 6: 53-59.
27. Thürmer HL, Lund-Larsen PG, Tverdal A. Is blood pressure treatment as effective in a population setting as in controlled trials? Results from a prospective study. J Hypertens 1994; 12: 481-490.
28. Merlo J et al. Incidence of myocardial infarction in elderly men being treated with antihypertensive drugs: population based cohort study. BMJ 1996; 313: 457-461.
29. Andersson OK et al. Survival in treated hypertension: follow up study after two decades. BMJ 1998; 317: 167-171.
30. Du X et al. Case-control study of stroke and the quality of hypertension control in north west England. BMJ 1997; 314: 272-276.
31. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
32. Shepherd J et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-1307.
33. Sacks FM et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
34. Downs JR et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-1622.
35. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998; 351: 233-241.
36. Haq IU, Jackson PR, Yeo WW, Ramsay LE. Implications of recent trials with lipid-lowering drugs for hypertension management. J Hypertens 1996; 14: 1502.
37. Hasnain S, Webster J, McLay JS. Cardiovascular risk in hypertension: implications of the Sheffield table for lipid-lowering strategy. J Hum Hypertens 1998; 12: 469-471.
38. Jackson R. Which hypertensive patients should be treated? Lancet 1994; 343: 496-497.
39. Kannel WB. Potency of vascular risk factors as the basis for antihypertensive therapy. Eur Heart J 1992; 13 (Suppl G): 34-42.
40. Alderman MH. Blood pressure management: individualized treatment based on absolute risk and the potential for benefit. Ann Intern Med 1993; 119: 329-335.
41. Davey Smith G, Egger M. Who benefits from medical interventions? Treating low risk patients can be a high risk strategy. BMJ 1994; 308: 72-74.
42. Ménard J, Chatellier G. Mild hypertension: the mysterious viability of a faulty concept. J Hypertens 1995; 13: 1071-1077.
43. Jackson RT, Sackett DL. Guidelines for managing raised blood pressure. Evidence based or evidence burdened? BMJ 1996; 313: 64-65.
44. Ramsay LE, Wallis EJ, Yeo WW, Jackson PR. The rationale for differing national recommendations for the treatment of hypertension. Am J Hypertens 1998; 11: 0009S-88S.
45. Core Services Committee. Guidelines for the management of mildly raised blood pressure in New Zealand. Ministry of Health: Wellington, 1995.
46. Swales JD. Treating hypertension. J Hypertens 1996; 14: 813-814.
47. Simpson FO. Guidelines for antihypertensive therapy: problems with a strategy based on absolute cardiovascular risk. J Hypertens 1996; 14: 683-689.
48. MacMahon S. Guidelines for antihypertensive therapy: a commentary. J Hypertens 1996; 14: 691-693.
49. Durrington PN et al. Indications for cholesterol owering medication: comparison of risk-assessment method. Lancet 1999; 353: 278-281.
50. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80 (Suppl 2): S1-S29.
51. Standing Medical Advisory Committee. The use of statins. Department of Health, London, 1997.
52. SIGN Guideline. Scottish intercollegiate guideline network; Lipids and the primary prevention of coronary heart disease, 1999.
53. Eccles M et al. North of England evidence based guideline development project. BMJ 1998; 316: 1303-1309.
54. O'Brien ET et al. Blood Pressure Measurement: Recommendations of the British Hypertension Society. BMJ Publishing Group, 3rd Edition, 1997.
55. Ramsay LE, Haq IU, Yeo WW, Jackson PR. Interpretation of prospective trials in hypertension: do treatment guidelines accurately reflect current evidence? J Hypertens 1996; 14 (Suppl 5): S187-S194.
56. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med 1993; 153: 598-615.
57. Peto R, Collins R. Antihypertensive drug therapy: effects on stroke and coronary heart disease. In: Swales JD (ed). Textbook of Hypertension. Blackwell: Oxford, 1994, pp 1156-1164.
58. Gueyffier F et al, Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomised controlled trials. Ann Intern Med 1997; 126: 761-767.
59. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-3204.
60. Fagard R, Staessen J, Thijs L, Amery A. Multiple standardized clinic blood pressures may predict left ventricular mass as well as ambulatory monitoring. A metaanalysis of comparative studies. Am J Hypertens 1995; 8: 533-540.
61. Fagard RH, Staessen JA, This L. Prediction of cardiac structure and function by repeated clinic and ambulatory blood pressure. Hypertension 1997; 29: 22-29.
62. Perloff D, Sokolow M, Cowan R. The prognostic value of ambulatory blood pressures. JAMA 1983; 249: 2792-2798.
63. Verdecchia P et al. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension 1994; 24: 793-801.
64. Staessen JA et al, for the Ambulatory Blood Pressure Monitoring and Treatment of Hypertension Investigators. Antihypertensive treatment based on conventional or ambulatory blood pressure measurement. A randomized controlled trial. JAMA 1997; 278: 1065-1072.
65. Haq IU et al. The impact of ambulatory blood pressure on estimation of cardiovascular risk in mild hypertension. J Hypertens 1997; 15: 1540-1541.
66. Mancia G, Zanchetti A. White-coat hypertension: misnomers, misconceptions and misunderstandings. What should we do next? J Hypertens 1995; 9: 1049-1052.
67. Parati G et al. Limitations of the difference between clinic and daytime blood pressure as a surrogate measure of the 'white-coat' effect. J Hypertens 1998; 15: 23-29.
68. Staessen JA, O'Brien ET, Atkins N, Amery AK. Ambulatory blood pressure in normotensive compared with hypertensive subjects. J Hypertens 1993; 11: 1289-1297.
69. Stergiou GS, Skeva II, Zourbaki AS, Mountokalakis TD. Self-monitoring of blood pressure at home: how many measurements are needed? J Hypertens 1998; 16: 725-731.
70. O'Brien E, Atkins N, Staessen J. State of the market. A review of ambulatory blood pressure monitoring devices. Hypertension 1995; 26: 835-842.
71. O'Brien E et al. The British Hypertension Society protocol for the evaluation of blood pressure measuring devices. J Hypertens 1993; 11 (Suppl 2): S43-S62.
72. Prisant LM et al. American National Standard for non-automated sphygmomanometers: summary report. Am J Hypertens 1995; 8: 210-213.
73. White WB et al. National standard for measurement of resting and ambulatory blood pressures with automated sphygmomanometers. Hypertension 1993; 21: 504-509.
74. National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group report on primary prevention of hypertension. Arch Intern Med 1993; 153: 186-208.
75. Watt GCM. Prevention of high blood pressure and its complications: strategic issues in a local context. J Hypertens 1995; 13: 377-383.
76. Whelton PK. Epidemiology of hypertension. Lancet 1994; 344: 101-106.
77. Stamler J. Setting the TONE for ending the hypertension epidemic. JAMA 1998; 279: 878-879.
78. Fortherby MD, Potter JF. Potassium supplementation reduces clinic and ambulatory blood pressure in elderly hypertensive patients. J Hypertens 1992; 10: 1403-1408.
79. Geleijnse JM et al. Reduction in blood pressure with a low sodium, high potassium, high magnesium salt in older subjects with mild to moderate hypertension. BMJ 1994; 309: 436-440.
80. Fotherby MD, Potter JF. Effects of moderate sodium restriction on clinic and twenty-four-hour ambulatory blood pressure in elderly hypertensive subjects. J Hypertens 1993; 11: 657-663.
81. Braith RW et al. Moderate-and high-intensity exercise lowers blood pressure in normotensive subjects 60-79 years of age. Am J Cardiol 1994; 73: 1124-1128.
82. Kokkinos PF et al. Effects of regular exercise on blood pressure and left ventricular hypertrophy in African-American men with severe hypertension. N Engl J Med 1995; 333: 1462-1467.
83. McCarron DA et al. Nutritional management of cardiovascular risk factors. A randomised clinical trial. Arch Intern Med 1997; 157: 169-177.
84. Singer DRJ et al. Reduction of salt intake during converting enzyme inhibitor treatment compared with addition of a thiazide. Hypertension 1995; 25: 1042-1044.
85. Law MR, Frost CD, Wald NJ. III-Analysis of data from trials of salt reduction. BMJ 1991; 302: 819-824.
86. Midgley JP, Matthew AG, Greenwood CMT, Logan AG. Effect of reduced dietary sodium on blood pressure. A meta-analysis of randomized controlled trials. JAMA 1996; 275: 1590-1597.
87. Kaplan NM. Alcohol and hypertension. Lancet 1995; 345: 1588-1589.
88. Gill JS et al. Stroke and alcohol consumption. N Engl J Med 1986; 315: 1041-1046.
89. McElduff P, Dobson A. How much alcohol and how often? Population based case-control study of alcohol consumption and risk of a major coronary event. BMJ 1997; 314: 1159-1164.
90. Arroll B, Beaglehole R. Exercise for hypertension. Lancet 1993; 341: 1248-1249.
91. Whelton PK et al. Effects of oral potassium on blood pressure: meta-analysis of randomized controlled clinical trials. JAMA 1997; 277: 1624-1632.
92. Williams C. Healthy eating: clarifying advice about fruit and vegetables. BMJ 1995; 310: 1453-1455.
93. Raw M, McNeill A, West R. Smoking cessation: evidence based recommendations for the healthcare system. BMJ 1999; 318: 182-185.
94. Tang JL et al. Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects. BMJ 1998; 316: 1213-1220.
95. OXCHECK Study. BMJ 1995; 310: 1099-1104.
96. Grover SA et al. Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study. BMJ 1995; 310: 975-978.
97. Evans J St BT, Harries C, Dennis I, Dean J. General practitioners' tacit and stated policies in the prescription of lipid lowering agents. Br J Gen Pract 1995; 45: 15-18.
98. Grover SA, Coupal L, Hu X-P. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? JAMA 1995; 274: 801-806.
99. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measurement of treatment effect. BMJ 1995; 310: 452-454.
100. Moser M. Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996; 27: 1214-1218.
101. Psaty BM et al. Health outcomes associated with anti-hypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997; 277: 739-745.
102. Liu L et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic hypertension in China (Syst-China) Collaborative group. J Hypertens 1998; 16: 1823-1829.
103. Hansson L et al. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP). Lancet 1999; 353: 611-615.
104. Thijs L et al. A meta-analysis of outcome trials in elderly hypertensives. J Hypertens 1992; 10: 1103-1109.
105. Siscovick DS et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994; 330: 1852-1857.
106. Carlsen JE, Kober L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 1990; 300: 975-978.
107. Whelton PK et al. Experimental approaches to determining the choice of first step therapy for patients with hypertension. The ALLHAT Research Group Antihypertensive and Lipid Lowering Treatment to prevent heart attack trial. Clin Exp Hypertens 1996; 18: 569-579.
108. Dahlof B, Sever PS, Poulter NR, Wedel H. On behalf of the ASCOT steering committee. J Hypertens 1998; 16 (Suppl 2): S212.
109. Packer M et al, for the Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335: 1107-1114.
110. Gong L et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996; 14: 1237-1245.
111. Beevers DG, Sleight P. Short acting dihydropyridine (vasodilating) calcium channel blockers for hypertension: is there a risk? BMJ 1996; 312: 1143-1145.
112. Materson BJ, Reda DJ, Cushman WC, Henderson WG, for the Department of Veterans Affairs Cooperative Study Group on Anti-hypertensive Agents. Results of combination anti-hypertensive therapy after failure of each of the components. J Hum Hypertens 1995; 9: 791-796.
113. Haq IU et al. Lipid-lowering for prevention of coronary heart disease: what policy now? Clin Sc 1996; 91: 399-413.
114. Lever AF, Ramsay LE. Treatment of hypertension in the elderly. J Hypertens 1995; 13: 571-579.
115. Kostis JB et al, for the SHEP Cooperative Research Group. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1997; 278: 212-216.
116. Forette F et al. Prevention of dementia in randomised placebo controlled systolic hypertension in Europe (SystEur) trial. Lancet 1998; 352: 1347-1357.
117. Levy D et al. The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557-1562.
118. Messerli FH, Grossman E, Goldbourt U. Are β-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998; 279: 1903-1907.
119. Adler A et al. Risk of macro vascular and micro vascular complications of diabetes at different levels of blood pressure - Observations from the UKPDS. Diabetes 1999; 48: A16.
120. Johnston CI, Cooper ME, Nicholls GM. Meeting report of the International Society of Hypertension conference on hypertension and diabetes. J Hypertens 1992; 10: 393-397.
121. Colhoun HM et al. The scope for cardiovascular disease risk factor intervention among people with diabetes in England. Diabetic Med 1999; 16: 35-40.
122. Colhoun HM, Williams B. The cardiovascular risk burden of diabetes mellitus. Acta Diabetilogia 1999; (in press).
123. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998; 352: 213-219.
124. Mogensen CE et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995; 346: 1080-1084.
125. Parving HH. Initiation and progression of diabetic nephropathy. N Engl J Med 1996; 335: 1682-1683.
126. Lazarus JM et al, for the Modification of Diet in Renal Disease Study Group. Achievement and safety of a low blood pressure goal in chronic renal disease. Hypertension 1997; 29: 641-650.
127. The Euclid Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normaoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-1792.
128. Williams B. Lisinopril and albumin excretion in diabetes. Lancet. 1997; 350: 663-664.
129. The Hypertension in Diabetes Study Group. Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993; 11: 309-317.
130. UKPDS Group. UKPDS 23: risk factors for coronary artery disease in non-insulin dependent diabetes. BMJ 1998; 316: 823-838.
131. UKPDS group 39. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 1998; 317: 713-720.
132. Curb JD et al. Effect of diuretic-based antihypertensive treatment on cardiovascular risk in people with diabetes. Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. JAMA 1996; 276: 1886-1892.
133. Gall MA, Hougaard P, Borch-Johnsen K, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ 1997; 314: 783-788.
134. Ravid M, Leug R, Rachmanni R, Lisner M. Long-term renoprotecive effect of angiotensin converting enzyme inhibitors in non-insulin dependent diabetes: a seven year follow-up. Arch Int Med 1996: 156: 286-289.
135. Williams B. Insulin resistance: the shape of things to come. Lancet 1994; 344: 521-524.
136. Madhaven S, Stockwell D, Cohen H, Alderman MH. Renal function during antihypertensive treatment. Lancet 1995; 345: 749-751.
137. Navis G, de Zeeuw D, de Jong PE. ACE-inhibitors: panacea for progressive renal disease? Lancet 1997; 349: 1852-1853.
138. Giatras I, Lau J, Levey AS, for the Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: A meta-analysis of randomized trials. Ann Intern Med 1997; 127: 337-345.
139. Gruppo Italiano di Studi Epidemiologici in Nefrologia. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-1863.
140. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure and the National High Blood Pressure Education Program Coordinating Committee. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413-2446.
141. Klahr S et al, for the Modification of Diet in Renal Disease Study Group. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 1994; 330: 877-884.
142. Wheeler DC. Cardiovascular disease in patients with chronic renal failure. Lancet 1996; 348: 1673-1674.
143. Broughton Pipkin F. The hypertensive disorders of pregnancy. BMJ 1995; 11: 609-613.
144. Sibai BM. Treatment of hypertension in pregnant women. N Engl J Med 1996; 335: 257-265.
145. Shennan A et al. Lack of reproducibility in pregnancy of Korotkoff phase IV as measured by mercury sphygmomanometry. Lancet 1996; 347: 139-142.
146. Rubin P. Measuring diastolic blood pressure in pregnancy. Use the fifth Korotkoff sound. BMJ 1996; 313: 4-5.
147. Collins R, Wallenburg HCS. Pharmacological prevention and treatment of hypertensive disorders in pregnancy. In: Chalmers I, Enkin M, Keirse MJNC (eds). Effective Care in Pregnancy and Childbirth. Vol 1: Pregnancy. Ch 24, 1992, pp. 382-402.
148. Kyle PM, Redman CW. Comparative risk-benefit assessment of drugs used in the management of hypertension in pregnancy. Drug Safety 1992; 7: 223-234.
149. Naden RP, Redman CW. Antihypertensive drugs in pregnancy. Clinics in Perinatol 1985; 12: 521-538.
150. Butters L, Kennedy S, Rubin PC. Atenolol in essential hypertension during pregnancy. BMJ 1990; 301: 587-589.
151. Collins R, Yusuf S, Peto R. Overview of randomized trials of diuretics in pregnancy. BMJ 1985; 290: 17-23.
152. Sibai BM, Grossman RA, Grossman HG. Effects of diuretics on plasma volume in pregnancies with long-term hypertension. Am J Obstetrics Gynaecol 1984; 150: 831-835.
153. Hansenns M, Keirse MJ, Vankelecom F, Van Assche FA. Fetal and neonatal effects of treatment with angiotensin converting enzyme inhibitors. Obstetrics and Gynecol 1991; 78: 128-135.
154. Nichols M et al. Effect of four combined oral contraceptives on blood pressure in the pill-free interval. Contraception 1993; 47: 367-376.
155. World Health Organisation. The WHO multicentre trial of the vasopressor effects of combined oral contraceptives, 1. Comparison with IUD. Contraception 1989; 40: 129-145.
156. Dong W, Colhoun HM, Poulter NR. Blood pressure in women using oral contraceptives: results from the health survey for Endlagnd 1994. J Hypertens 1998; 15: 1063-1068.
157. Wier RJ. Oral contraceptives, hormone replacement therapy and hypertension. In: Swales JD (ed). Textbook of hypertension. Oxford Blackwell Scientific Publications: Oxford, 1994, pp 904-922.
158. Lim KG et al. Malignant hypertension in women of childbearing age and its relation to the contraceptive pill. BMJ 1987; 294: 1057-1059.
159. World health organisation collaborative study of cardiovascular disease and steroid hormonec contraception. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case control study. Lancet 1996; 348: 498-505.
160. Wilson ESB, Cruickshank J, McMaster M, Weir RJ. A propsective controlled study of the effect on blood pressure of contraceptive preparations containing different types of progestagen. Br J Ostet Gynaecol 1984: 91; 1254-1260.
161. Nabulsi AA et al. Association of hormone-replacement therapy with various cardiovascular risk factors in post-menopausal women. The Atherosclerosis Risk in Communities Investigators. N Engl J Med 1993; 328: 1069-1075.
162. The writing group for the PEPI trial. Effect of oestrogen or oestrogen/progestin regimens on heart disease risk factors in post-meopausal women. JAMA 1995; 273: 199-208.
163. Hulley S et al. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. JAMA 1998; 280: 605-613.
164. Cappuccio FP, Cook DG, Atkinson RW, Strazzullo P. Prevalence, detection, and management of cardiovascular risk factors in different ethnic groups in south London. Heart 1997; 78: 555-563.
165. Relation of central obesity and insulin resistance with diabetes prevalence and cardiovascular risk in south Asians. Lancet 1991; 337: 382-386.
166. Williams B. Westernised Asians and cardiovascular disease: Nature or nuture? Lancet 1995; 345: 401-402.
167. Balarajan R. Ethnic differences in mortality from ischaemic heart disease and cerebrovascular disease in England and Wales. BMJ 1991; 302: 560-564.
168. Wilhelmsen L, Strasser T, on behalf of the Study Collaborators. WHO-WHL hypertension management audit project. J Hum Hypertens 1993; 7: 257-263.
169. Carney S, Gillies A, Smith A, Taylor M. Hypertension education: patient knowledge and satisfaction. J Hum Hypertens 1993; 7: 505-508.
170. Taylor FC, Ebrahim S. Prevention of cardiovascular disease in hypertensive patients in general practice: improving the quality of care. Br J Cardiol 1997; 4: 331-335.